相关实验视频

Updated: Jul 9, 2025

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

除了血糖控制之外:对SGLT-2抑制剂在心力衰竭管理中的机制性见解

Shreya Garg¹, Sai Gautham Kanagala², Fnu Anamika³

¹From the Department of Internal Medicine, Dayanand Medical College & Hospital, Punjab, India.

Cardiology in review

|November 29, 2023

概括

-葡萄糖共传输体-2 抑制剂通过减少心肌细胞重塑来治疗心力衰竭具有前景. 这些药物对糖尿病患者和非糖尿病患者都有好处,提供了一种超越传统疗法的新方法.

科学领域:

心脏病学心脏病学
内分泌学在内分泌学.
药理学药理学是指药理学的学科.

背景情况:

心力衰竭 (HF) 是致病率和死亡率的主要原因,通常与糖尿病和高血压等并发症有关.
传统的HF治疗包括利尿剂和Renin-Angiotensin-Aldosterone系统抑制剂.
心肌细胞重塑是心力衰竭发展中的关键病理过程.

研究的目的:

审查通过-葡萄糖共运输体-2 (SGLT2) 抑制剂影响心肌细胞重塑的分子机制.
探索SGLT2抑制剂作为糖尿病和非糖尿病患者心力衰竭的辅助疗法的潜力.

主要方法:

审查最近研究SGLT2抑制剂及其对心肌细胞的影响的研究.
对参与SGLT2抑制介导心脏保护的分子通路的分析.
对心力衰竭人群中SGLT2抑制剂使用的临床数据的检查.

主要成果:

SGLT2 抑制剂对心肌细胞重塑具有有益作用,独立于血糖控制.
有证据表明,这些药物可以减轻心肌细胞内的病理变化.
新出现的数据支持它们在不同心力衰竭患者群体中的有效性.

结论:

SGLT2 抑制剂通过向心肌细胞重塑来代表心力衰竭的新疗法策略.
它们的使用可能超出糖尿病管理范围,以改善心血管结果.
需要进一步的研究,以充分阐明它们在综合性心力衰竭治疗中的作用.

更多相关视频

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

相关概念视频

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Glucose Transporters

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...